Enhertu and Datroway approved in Japan for two new 1L indications in metastatic Breast cancer

ELAHERE approved in Japan for patients with FRα-positive, platinum-resistant recurrent Ovarian cancer

SYS6010 received NMPA BTD in China for actionable genomic alteration-negative non-squamous NSCLC

Hengrui’s HER3 ADC, SHR-A2009 for injection, included in China’s Breakthrough Therapy list for NSCLC

Sino Biopharmaceutical announces NDA acceptance for TQB2102 in HER2-low Breast cancer in China

Escugen and Sovran expand collaboration to co-develop a novel bispecific ADC